Tags

Type your tag names separated by a space and hit enter

The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
Clin Endocrinol (Oxf). 2005 May; 62(5):607-10.CE

Abstract

OBJECTIVE

Obesity is a metabolic disorder that is associated with increased plasminogen activator inhibitor-1 (PAI-1) concentration in the circulation. This increase is related to insulin resistance, dyslipidaemia and cardiovascular disease. Some studies have demonstrated a relationship between plasma PAI-1 concentrations and the 4G/5G gene polymorphism in the PAI-1 gene, while other studies have not. It is well known that plasma PAI-1 levels are increased in obesity; however, the relationship between the polymorphism and obesity remains unclear. In this study, we aimed to elucidate the effect of the PAI-1 4G/5G polymorphism on glucose and lipid metabolism parameters in Turkish obese children.

DESIGN AND PATIENTS

Ninety children with obesity (37 male, 53 female; mean age 11.1 +/- 3.4 years; range 5.8-17.6 years) were included in the study. The children were divided into three groups according to the PAI-1 promoter 4G/5G polymorphism (4G/4G, 4G/5G and 5G/5G). These groups were compared for age, body mass index (BMI), serum glucose, lipid and insulin levels, and homeostasis model assessment of insulin resistance (HOMA-IR) score.

RESULTS

The genotype distribution was 52% (47/90) 4G/4G, 25% (22/90) 4G/5G and 23% (21/90) 5G/5G. No statistically significant differences among genotype groups were found with respect to age, BMI, serum levels of glucose, lipid and insulin, and HOMA-IR score.

CONCLUSION

Although the frequency of the 4G/4G genotype was higher in subjects in the current study than in subjects reported in the literature, in our study group we observed no influence of the PAI-1 4G/4G polymorphism on lipid and glucose metabolism.

Authors+Show Affiliations

Kinik ST
Department of Paediatrics, Division of Paediatric Endocrinology, Baskent University Faculty of Medicine, Ankara, Turkey. stkinik@hotmail.com
Ataç FB
No affiliation info available
Verdi H
No affiliation info available
Cetintaş S
No affiliation info available
Sahin FI
No affiliation info available
Ozbek N
No affiliation info available

MeSH

AdolescentBlood GlucoseChildChild, PreschoolFemaleGene FrequencyHomeostasisHumansInsulinInsulin ResistanceLipid MetabolismLipidsMaleObesityPlasminogen Activator Inhibitor 1Polymorphism, GeneticPromoter Regions, GeneticTurkey

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15853833

Citation

Kinik, Sibel Tulgar, et al. "The Effect of Plasminogen Activator Inhibitor-1 Gene 4G/5G Polymorphism On Glucose and Lipid Metabolisms in Turkish Obese Children." Clinical Endocrinology, vol. 62, no. 5, 2005, pp. 607-10.
Kinik ST, Ataç FB, Verdi H, et al. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children. Clin Endocrinol (Oxf). 2005;62(5):607-10.
Kinik, S. T., Ataç, F. B., Verdi, H., Cetintaş, S., Sahin, F. I., & Ozbek, N. (2005). The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children. Clinical Endocrinology, 62(5), 607-10.
Kinik ST, et al. The Effect of Plasminogen Activator Inhibitor-1 Gene 4G/5G Polymorphism On Glucose and Lipid Metabolisms in Turkish Obese Children. Clin Endocrinol (Oxf). 2005;62(5):607-10. PubMed PMID: 15853833.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children. AU - Kinik,Sibel Tulgar, AU - Ataç,F Belgin, AU - Verdi,Hasibe, AU - Cetintaş,Sedat, AU - Sahin,Feride I, AU - Ozbek,Namik, PY - 2005/4/28/pubmed PY - 2005/7/15/medline PY - 2005/4/28/entrez SP - 607 EP - 10 JF - Clinical endocrinology JO - Clin Endocrinol (Oxf) VL - 62 IS - 5 N2 - OBJECTIVE: Obesity is a metabolic disorder that is associated with increased plasminogen activator inhibitor-1 (PAI-1) concentration in the circulation. This increase is related to insulin resistance, dyslipidaemia and cardiovascular disease. Some studies have demonstrated a relationship between plasma PAI-1 concentrations and the 4G/5G gene polymorphism in the PAI-1 gene, while other studies have not. It is well known that plasma PAI-1 levels are increased in obesity; however, the relationship between the polymorphism and obesity remains unclear. In this study, we aimed to elucidate the effect of the PAI-1 4G/5G polymorphism on glucose and lipid metabolism parameters in Turkish obese children. DESIGN AND PATIENTS: Ninety children with obesity (37 male, 53 female; mean age 11.1 +/- 3.4 years; range 5.8-17.6 years) were included in the study. The children were divided into three groups according to the PAI-1 promoter 4G/5G polymorphism (4G/4G, 4G/5G and 5G/5G). These groups were compared for age, body mass index (BMI), serum glucose, lipid and insulin levels, and homeostasis model assessment of insulin resistance (HOMA-IR) score. RESULTS: The genotype distribution was 52% (47/90) 4G/4G, 25% (22/90) 4G/5G and 23% (21/90) 5G/5G. No statistically significant differences among genotype groups were found with respect to age, BMI, serum levels of glucose, lipid and insulin, and HOMA-IR score. CONCLUSION: Although the frequency of the 4G/4G genotype was higher in subjects in the current study than in subjects reported in the literature, in our study group we observed no influence of the PAI-1 4G/4G polymorphism on lipid and glucose metabolism. SN - 0300-0664 UR - https://www.unboundmedicine.com/medline/citation/15853833/The_effect_of_plasminogen_activator_inhibitor_1_gene_4G/5G_polymorphism_on_glucose_and_lipid_metabolisms_in_Turkish_obese_children_ DB - PRIME DP - Unbound Medicine ER -